http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CU-20120137-A7

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6572ff5df928fd17340eb2a8cb6d8502
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C231-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C233-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C231-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165
filingDate 2012-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24b15ac09fe42a689adf022f7c01c408
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b29fbd4963dc6e08a3fafc809bcdc939
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b26dc23f2d272f8797b0e3750fa13a7f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c725269abc2b4a95882af617e9e5452
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8448732ce280b597a98e15053d5272e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b36a712b5cc604743111b05948fb23f
publicationDate 2012-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CU-20120137-A7
titleOfInvention HYDROCHLORIDE HYDROCHLORIDE HYDROCHLORIDE AND PREPARATION OF THIS
abstract An agomelatine hydrochloride hydrate of formula (I) is provided, wherein X is CI, preparation, use and pharmaceutical composition thereof. Said hydrate obtained by the present method has a significantly increased solubility than agomelatine, and is therefore more suitable for manufacturing pharmaceutical formulations. Using the present method, high purity can be obtained by a simple process, without any complicated stage. FORMULA SPACE
priorityDate 2010-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454550740
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453887929
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21873664
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66980040
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID82148
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419480088

Total number of triples: 35.